共 463 条
[1]
Abrams P(2002)The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society (ICS) Neurourol Urodyn 21 167-178
[2]
Cardozo L(2010)Social, economic, and health utility considerations in the treatment of overactive bladder Open Access J Urol 2 11-24
[3]
Fall M(2012)Physiopathology of overactive bladder syndrome Urologia 79 24-35
[4]
Sacco E(2008)The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 54 543-562
[5]
Tienforti D(2012)Mirabegron: a review of recent data and its prospects in the management of overactive bladder Ther Adv Urol 4 315-324
[6]
D’Addessi A(2012)Future perspective in pharmacological treatment options for overactive bladder syndrome Eur Urol Rev 7 120-126
[7]
Sacco E(2008)Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences Int Urogynecol J Pelvic Floor Dysfunct 19 583-598
[8]
Chapple CR(2007)Effects of imidafenacin (KRP-197/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland Arzneimittelforschung 57 92-100
[9]
Khullar V(2011)Comparative evaluation of the safety and efficacy of long-term use of imidafenacin and solifenacin in patients with overactive bladder: a prospective, open, randomized, parallel-group trial (the LIST study) Adv Urol 2011 854697-506
[10]
Gabriel Z(2009)A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder Int J Urol 16 499-196